View in EDS HTML Full Text PDF Full Text

Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial.

Saved in:
Bibliographic Details
Title: Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial.
Authors: Squire IB; NIHR Biomedical Research Centre, Glenfield Hospital, Leicester, UK.; Department of Cardiovascular Sciences, University of Leicester, Leicester, UK., Gabrielsen A; Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Greasley PJ; Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Wernevik L; Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Hartleib-Geschwindner J; Late-stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Holden J; Global Drug Safety, Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA., Johansson S; Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Rudvik A; Early Biometrics and Statistical Innovation, Data Science and AI, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Sánchez J; Early Biometrics and Statistical Innovation, Data Science and AI, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Bamberg K; Translational Sciences and Experimental Medicines, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Melin J; Clinical & Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Whittaker A; Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Source: Clinical and translational science [Clin Transl Sci] 2022 Oct; Vol. 15 (10), pp. 2493-2504. Date of Electronic Publication: 2022 Aug 20.
Publication Type: Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1752-8062 (Electronic) Linking ISSN: 17528054 NLM ISO Abbreviation: Clin Transl Sci Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35971596
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Squire+IB%22">Squire IB</searchLink>; NIHR Biomedical Research Centre, Glenfield Hospital, Leicester, UK.; Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.<br /><searchLink fieldCode="AU" term="%22Gabrielsen+A%22">Gabrielsen A</searchLink>; Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Greasley+PJ%22">Greasley PJ</searchLink>; Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Wernevik+L%22">Wernevik L</searchLink>; Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Hartleib-Geschwindner+J%22">Hartleib-Geschwindner J</searchLink>; Late-stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Holden+J%22">Holden J</searchLink>; Global Drug Safety, Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Johansson+S%22">Johansson S</searchLink>; Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Rudvik+A%22">Rudvik A</searchLink>; Early Biometrics and Statistical Innovation, Data Science and AI, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Sánchez+J%22">Sánchez J</searchLink>; Early Biometrics and Statistical Innovation, Data Science and AI, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Bamberg+K%22">Bamberg K</searchLink>; Translational Sciences and Experimental Medicines, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Melin+J%22">Melin J</searchLink>; Clinical & Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Whittaker+A%22">Whittaker A</searchLink>; Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101474067%22">Clinical and translational science</searchLink> [Clin Transl Sci] 2022 Oct; Vol. 15 (10), pp. 2493-2504. <i>Date of Electronic Publication: </i>2022 Aug 20.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22WileyBlackwell+Pub%22">WileyBlackwell Pub </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101474067 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1752-8062 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2217528054%22">17528054 </searchLink><i>NLM ISO Abbreviation: </i>Clin Transl Sci <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35971596
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/cts.13377
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2493
    Titles:
      – TitleFull: Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Squire IB
      – PersonEntity:
          Name:
            NameFull: Gabrielsen A
      – PersonEntity:
          Name:
            NameFull: Greasley PJ
      – PersonEntity:
          Name:
            NameFull: Wernevik L
      – PersonEntity:
          Name:
            NameFull: Hartleib-Geschwindner J
      – PersonEntity:
          Name:
            NameFull: Holden J
      – PersonEntity:
          Name:
            NameFull: Johansson S
      – PersonEntity:
          Name:
            NameFull: Rudvik A
      – PersonEntity:
          Name:
            NameFull: Sánchez J
      – PersonEntity:
          Name:
            NameFull: Bamberg K
      – PersonEntity:
          Name:
            NameFull: Melin J
      – PersonEntity:
          Name:
            NameFull: Whittaker A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 10
              Text: 2022 Oct
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1752-8062
          Numbering:
            – Type: volume
              Value: 15
            – Type: issue
              Value: 10
          Titles:
            – TitleFull: Clinical and translational science
              Type: main
ResultId 1